Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
about
Adoptive immunotherapy for cancer: building on successT cell avidity and tumor recognition: implications and therapeutic strategies.PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumabHuman antigen-specific regulatory T cells generated by T cell receptor gene transfer.Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity.Strategies to genetically engineer T cells for cancer immunotherapy.Genomic analysis of CD8+ NK/T cell line, 'SRIK-NKL', with array-based CGH (aCGH), SKY/FISH and molecular mapping.MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitroFocus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaUse of tumour-responsive T cells as cancer treatment.High-avidity T cells are preferentially tolerized in the tumor microenvironmentHigh-titre retroviral vector system for efficient gene delivery into human and mouse cells of haematopoietic and lymphocytic lineages.Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression.Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor.Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy.Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.T-cell receptor gene therapy for cancer: the progress to date and future objectives.TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumorsRole of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma.Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells.Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+) CD25(-) and CD8(+) T cells attenuates effector function.Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression.Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.Characterization of the human CD4(+) T-cell repertoire specific for major histocompatibility class I-restricted antigens.Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.
P2860
Q24546258-42EF8979-0085-4B0C-BB9A-630437F2C36FQ24815775-713DE29F-8F52-47C3-84AF-EFA8F9B98DFCQ28073874-F3A54008-E4E7-483C-92EE-9AE158FD78EBQ33644234-858601EE-1364-418D-BDE1-625205F5489DQ33649735-1E7DB7F7-52C4-4977-840D-0B58ABFADB10Q33655849-5C13A38F-4562-491B-B52A-49092421BB8AQ33793137-3B4D2B5D-08A2-43ED-86E1-5699EB0A3B99Q34050163-4A34BE9D-BD9A-401C-8A19-693AC6481D6EQ34111789-48A9A378-417C-442F-A2AD-A5C8288B78E6Q34285656-3FCC8F3C-1DB0-4C4F-9879-CE1E847EDDECQ34463820-4979FDA8-9885-44E2-9252-1E8102CE5EC5Q34641722-B395CF50-25B0-416D-97C1-9A351187A6DFQ34657661-A63A97EB-15E0-4FAE-AE45-28F0A6760121Q35866186-9A85B89E-7D8B-4E09-A5B0-A913FFE08841Q36237834-9F61B23F-179C-4074-A814-9D5AEEE69051Q36239656-6E23F303-B0E7-4C68-AED3-343FC0D65E33Q36286122-C54163E8-BD96-4D3E-8C21-5BA678EA3BA2Q36286127-DE61D7B8-4F67-4D89-9D72-CEA64BA94CE0Q36453570-4CA13FE4-97EB-4F9B-A1CB-B61B268AFD9AQ36616920-DCB55A33-8F77-474A-9533-2715EAC33339Q36842738-6657123E-3024-4830-AE9C-77B314B791D0Q36909378-53BA88FC-27EA-478A-B6E0-E8E9E120ADADQ36951685-CD282311-ECD2-4725-98A3-95526D9EB5F7Q37107843-91714D33-5FF1-4237-834B-60A2FF3E4EE0Q37275680-0763F49D-0751-4E17-990D-494CB7210BE6Q37412169-535F1A1D-F7B0-412E-980C-482628FC5AADQ37462768-5975143C-4A6E-4FED-9FED-59220B4F4083Q37474050-EBE34737-5A6C-464B-99A2-8D5B1221B164Q38595264-27FD89A3-5AE3-49EE-BD66-C50ADB31F2E0Q38672403-334EA0F9-FE86-4E5D-8244-E23524BBE1C6Q38763198-BD70411B-B7B8-4326-990C-0E16C972E933Q38930056-8583D93B-8744-4AD2-9C6C-863D9B4F2D98Q39418029-C34C9608-BDCD-44E9-8509-E6624CF00AF8Q39835934-0E70DE76-F0EB-48D4-98DB-2B72F0F1F9E7Q39964234-344ABE14-C7A7-48D4-A7AD-C4CF4BE6ED31Q40151758-064AE012-CEEE-4B84-B814-A7582D0A051AQ41143349-C1E68961-E94F-4FDB-B69A-47A1BA7C3C3CQ42136462-A6882DF5-7AF0-4B68-930E-E1AA27DF40D5Q42275373-9B29FE32-4E69-4F2E-B2E0-2192904BB6CBQ45882718-593988A5-4987-456F-8E28-87885975CC24
P2860
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Simultaneous generation of CD8 ...... r of a single T-cell receptor.
@en
type
label
Simultaneous generation of CD8 ...... r of a single T-cell receptor.
@en
prefLabel
Simultaneous generation of CD8 ...... r of a single T-cell receptor.
@en
P2093
P1433
P1476
Simultaneous generation of CD8 ...... r of a single T-cell receptor.
@en
P2093
Cassian Yee
Gretchen E Lyons
Jeffrey J Roszkowski
Koen Van Besien
Michael I Nishimura
W Martin Kast
P304
P356
10.1158/0008-5472.CAN-04-2076
P407
P577
2005-02-01T00:00:00Z